ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is compared to…
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.
Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.
AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.
Chris Lange Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the doghouse?
Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
Friday's top analyst upgrades, downgrades and initiations include Harley-Davidson, Lululemon, Nike, SunPower and Walmart.
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held short as of October 15 experienced a decline in short interest.
